Live Earnings Conference Call: ANI Pharmaceuticals will host a live Q3 2026 & Acquisition earnings call on November 5, 2026 at 9:00AM ET. Follow this link to get details and listen to ANI Pharmaceuticals' Q3 2026 & Acquisition earnings call when it goes live. Get details. NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $71.65 -0.63 (-0.87%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$73.01 +1.36 (+1.89%) As of 07:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ANI Pharmaceuticals Stock (NASDAQ:ANIP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$71.36▼$74.0050-Day Range$70.16▼$78.8552-Week Range$69.58▼$95.57Volume304,428 shsAverage Volume340,775 shsMarket Capitalization$1.65 billionP/E Ratio15.44Dividend YieldN/APrice Target$99.60Consensus RatingHold Company Overview ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders. ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases. Its products include Cortrophin-Zinc, a repository corticotropin injection used for certain inflammatory and autoimmune conditions, along with a range of other prescription therapies. The company also maintains a pipeline of internally developed, acquired and partnered products. ANI Pharmaceuticals primarily serves the United States through its commercial, manufacturing and distribution operations. The company’s corporate headquarters are in Princeton, New Jersey, and it operates pharmaceutical manufacturing and development facilities in the United States. Nikhil Lalwani serves as president and chief executive officer.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreANIP MarketRank™: 4.287732041965 of 5 starsANI Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 49th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingANI Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 3 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialANI Pharmaceuticals has a consensus price target of $99.60, representing about 39.0% upside from its current price of $71.65.Amount of Analyst CoverageANI Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth7.22% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 7.22% in the coming year, from $7.76 to $8.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 15.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.31.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 15.44, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.06.Price to Earnings Growth RatioANI Pharmaceuticals has a PEG Ratio of 2.33. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.45% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 0.55%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.64 News SentimentANI Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,220,970.00 in company stock.Percentage Held by Insiders8.10% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesANI Pharmaceuticals Reports Third Quarter 2026 Financial Results40 minutes ago | globenewswire.comREPEAT – ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease Business50 minutes ago | globenewswire.comThe government is buying stocksDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 5 at 1:00 AM | Porter & Company (Ad)ANI Pharmaceuticals Announces Offer to Acquire Egetis Therapeutics, Expanding the Scope and Scale of Its Rare Disease BusinessNovember 5 at 1:33 AM | globenewswire.comWhat to expect from ANI Pharmaceuticals’s (ANIP) Q3 earningsNovember 4 at 1:50 AM | msn.comInsider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) CFO Sells $207,679.50 in StockOctober 31, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells $388,206.00 in StockOctober 17, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares of StockOctober 14, 2026 | insidertrades.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $78.94 at the beginning of 2026. Since then, ANIP stock has decreased by 9.2% and is now trading at $71.65. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings data on Friday, August, 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping the consensus estimate of $2.04 by $0.17. The company's revenue was up 25.8% compared to the same quarter last year. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional shareholders include Penn Capital Management Company LLC (0.93%), Bridge City Capital LLC (0.23%), Profund Advisors LLC (0.10%) and Artemis Investment Management LLP (0.09%). Insiders that own company stock include Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Thomas Haughey, Patrick D Walsh, Thomas Andrew Rowland, Jeanne Thoma, Renee P Tannenbaum, Antonio R Pera and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings8/07/2026Today11/04/2026Next Earnings (Estimated)11/05/20263rd Annual Guggenheim Healthcare Innovation Conference11/10/2026Jefferies Global Healthcare Conference11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ANIP's financial health is in the Red zone, according to TradeSmith. ANIP has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees970Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$99.60 High Price Target$119.00 Low Price Target$85.00 Potential Upside/Downside+39.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$4.64 Trailing P/E Ratio15.44 Forward P/E Ratio8.61 P/E Growth2.33Net Income$78.34 million Net Margins11.07% Pretax Margin14.57% Return on Equity27.37% Return on Assets10.47% Debt Debt-to-Equity Ratio0.99 Current Ratio2.91 Quick Ratio2.41 Sales & Book Value Annual Sales$883.37 million Price / Sales1.86 Cash Flow$9.84 per share Price / Cash Flow7.28 Book Value$24.03 per share Price / Book2.98Miscellaneous Outstanding Shares22,970,000Free Float21,109,000Market Cap$1.65 billion OptionableOptionable Beta0.45 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ANIP) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | Sponsored$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get a...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
